CINCINNATI--(BUSINESS WIRE)-- Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from ...

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics has provided a regulatory update on NUZ-001, its ...

NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...

Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...

On Wednesday, Verge Genomics announced that Eli Lilly And Co (NYSE:LLY) has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that ...

Pennington Biomedical’s Dr. Jeff Keller and Dr. Aron Culotta of Tulane to lead collaboration of AI researchers, neuroscientist and drug developers Answer ALS is proud to announce the launch of a ...

AB Science SA (Euronext – FR0010557264 – AB) today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, ...

ALS, which is also known as Lou Gehrig’s Disease, is a rare neurological disease that affects motor neurons — the nerve cells. Why are so many amyotrophic lateral sclerosis (ALS) drug trials are ...